Coherus BioSciences Files Definitive Proxy Statement

TL;DR

Coherus BioSciences filed its proxy statement, shareholders will vote on company matters soon.

AI Summary

Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on May 13, 2024. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The filing does not contain specific financial figures or details about upcoming votes but serves as official notification to shareholders.

Why It Matters

This filing is a standard regulatory requirement for public companies, informing shareholders about upcoming meetings and voting procedures. It ensures transparency and shareholder participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new financial information or significant corporate actions that would immediately impact stock price.

Key Players & Entities

• Coherus BioSciences, Inc. (company) — Registrant
• Dennis M. Lanfear (person) — Contact Person for Business and Mail Address
• 20240513 (date) — Filing Date

FAQ

Key Financial Figures

• $280,854 — Options outstanding 116,537 0.1% $280,854 Weighted average exercise price of ou
• $10,428,246 — ptions outstanding 4,327,073 3.8% $10,428,246 Weighted average exercise price of ou
• $40,165 — ock units outstanding 16,666 0.0% $40,165 Restricted stock awards outstanding
• $57,836,662 — ions outstanding 23,998,615 20.9% $57,836,662 Weighted average exercise price of ou
• $2,188,121 — ck units outstanding 907,934 0.8% $2,188,121 Restricted stock awards outstanding
• $174,221 — e under the 2014 Plan 72,921 0.1% $174,221 Restated Plan Proposed increase to
• $16,870,000 — e under 2014 Plan) 7,000,000 6.1% $16,870,000 (1) Based on 114,715,019 shares of ou
• $2.41 — our common stock on April 11, 2024, of $2.41 per share. (3) Does not reflect 2,148

Filing Documents

• tmb-20240513xdefa14a.htm (DEFA14A) — 70KB
• tmb-20240513xdefa14a001.jpg (GRAPHIC) — 4KB
• 0001558370-24-007976.txt ( ) — 77KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Coherus BioSciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. COHERUS BIOSCIENCES, INC. 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 SUPPLEMENT TO PROXY STATEMENT DATED APRIL 15, 2024 FOR ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 29, 2024 Proxy Statement Supplement To the Stockholders of Coherus BioSciences, Inc.: This proxy statement supplement dated May 13, 2024 (this "Supplement") supplements the proxy statement (the "Proxy Statement") filed by Coherus BioSciences, Inc., a Delaware corporation (the "Company" or "we"), with the Securities and Exchange Commission on April 15, 2024 for the 2024 annual meeting of stockholders (the "Annual Meeting") to be held on May 29, 2024 at 1:30 p.m. PDT via the internet at www.virtualshareholdermeeting.com/CHRS2024. This Supplement should be read in conjunction with the Proxy Statement, and except as updated by this Supplement, all information set forth in the Proxy Statement remains unchanged and should be considered in casting your vote by proxy or at the Annual Meeting. The purpose of this Supplement is to clarify certain details under Proposal No. 4 in the Proxy Statement, in which we ask our stockholders to approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan"). The amended and restated 2014 Plan is referred to herein as the "Restated Plan." The following information supplements and clarifies Proposal No. 4 in the Proxy Statement: The effective date of the Restated Plan is April 11, 2024, which is the date our Board of Directors approved the Restated Plan, subject to stockholder approval. All references to the "effective date" of the Restated Plan in Proposal No. 4 refer to April 11, 2024. No new awards have been made under the Company's 2016 Employment Commencement Incentive Plan, or the Inducement Plan, since April 11, 2024, nor will any future awards be made under the Inducement Plan if stockholders approve the Restated Plan. Proposal No. 4 presents certain information regarding Company shares and awards outstanding as of April 9, 2024, which is the record date for the Annual Meeting. Given the effective date of the Restated Plan is April 11, 2024, we would like to also present the following information as of April 11, 2024: - As of April 11, 2024, a total of 25,287,510 shares of our common stock were reserved under the 2014 Plan, the aggregate number of shares of common stock subject to awards under the 2014 Plan was 23,998,615 and a total of 1,288,895 shares of common stock remained available under the 2014 Plan for future issuance. - As of April 11, 2024, after adjusting for an aggregate 1,216,604 fully-vested RSUs granted and released on April 12, 2024 to certain of our current and former employees, a total of 24,070,906 shares of our common stock were reserved under the 2014 Plan, the aggregate number of shares of common stock subject to awards under the 2014 Plan was 23,998,615 and a total of 72,291 shares of common stock remained available under the 2014 Plan for future issuance - The table below presents information as of April 11, 2024 about the number of shares that were subject to various outstanding equity awards under our equity plans, and the shares remaining available for issuance under each such plan, after adjusting for an aggregate 1,216,604 fully-vested RSUs granted and released on April 12, 2024 to certain of our current and former employees. The existing 2014 Plan and the Inducement Plan are the only equity incentive plans we currently have in place under which we can grant awards (other than the shares available for purchase under our 2014 Employee Stock Purchase Plan). As noted above, no new awards have been made under the Inducement Plan since April 11, 2024, nor will any future awards be made under the Inducement Plan if stockholders approve the Restated Plan. Number of Shares and Related Information As a % of Shares Outstanding(1) Dollar Value (2) Prior Plan Options outstanding 116,537 0.1% $280,854 Weighted average exercise price of outstanding options $ 10.20 Weighted average exercise remaining term of outstan

View Full Filing

View this DEFA14A filing on SEC EDGAR